🔍
Search Results - j.+ippoliti
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Novel Oxazolidinone Antibacterials and the Synthetic Routes to Them
Marketing Summary Draft Novel Oxazolidinone Antibacterials and the Synthetic Routes to ThemJHU Ref #: C18144Value Proposition· Higher efficacy and lower toxicity oxazolidinone compounds· Positive activity demonstrated against M. abscessus· MIC values are the same or better than the current antibiotics in the market Unmet Need The...
Published: 3/14/2025
|
Inventor(s):
Gyanu Lamichhane
,
J. Ippoliti
,
Cole Friederichs
,
Connor Winkelhake
,
Ben Thompson
,
Kelsey Latterell
Keywords(s):
Category(s):
Novel Oxazolidinones for Treatment of Bacterial Infections
Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...
Published: 3/13/2025
|
Inventor(s):
Gyanu Lamichhane
,
J. Ippoliti
Keywords(s):
Bacterial Infections
,
Disease Indication
,
Infectious Diseases
,
Novel
,
Predicted Novelty
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Clinical and Disease Specializations > Infectious Diseases
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections
An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria
TITLE: An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive BacteriaCASE NUMBER: C13966UNMET NEEDTuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant...
Published: 3/13/2025
|
Inventor(s):
Gyanu Lamichhane
,
J. Ippoliti
Keywords(s):
Bacterial Infections
,
Disease Indication
,
Infectious Diseases
,
Novel
,
Predicted Novelty
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Tuberculosis
,
Tuberculosis (TB)
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections
,
Clinical and Disease Specializations > Infectious Diseases > Tuberculosis
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Clinical and Disease Specializations > Infectious Diseases
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum